AMARYL Drug Patent Profile

Which patents cover Amaryl, and what generic alternatives are available?

Amaryl is a drug marketed by Sanofi Aventis Us and is included in one NDA.

The generic ingredient in AMARYL is glimepiride. There are sixteen drug master file entries for this compound. Twenty-nine suppliers are listed for this compound. Additional details are available on the glimepiride profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Amaryl

A generic version of AMARYL was approved as glimepiride by CHARTWELL MOLECULAR on October 6^th, 2005.

Summary for AMARYL

US Patents:	0
Applicants:	1
NDAs:	1
Raw Ingredient (Bulk) Api Vendors:	141
Clinical Trials:	69
Patent Applications:	4,275
Drug Prices:	Drug price information for AMARYL
What excipients (inactive ingredients) are in AMARYL?	AMARYL excipients list
DailyMed Link:	AMARYL at DailyMed

See drug prices for AMARYL

See drug sales revenues for AMARYL

Recent Clinical Trials for AMARYL

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
Damanhour University	N/A
PT Pharma Metric Labs	N/A
PT Harsen Laboratories	N/A

See all AMARYL clinical trials

US Patents and Regulatory Information for AMARYL

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Sanofi Aventis Us	AMARYL	glimepiride	TABLET;ORAL	020496-001	Nov 30, 1995		DISCN	Yes	No
Sanofi Aventis Us	AMARYL	glimepiride	TABLET;ORAL	020496-002	Nov 30, 1995		DISCN	Yes	No
Sanofi Aventis Us	AMARYL	glimepiride	TABLET;ORAL	020496-003	Nov 30, 1995		DISCN	Yes	No

Expired US Patents for AMARYL

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Sanofi Aventis Us	AMARYL	glimepiride	TABLET;ORAL	020496-001	Nov 30, 1995
Sanofi Aventis Us	AMARYL	glimepiride	TABLET;ORAL	020496-002	Nov 30, 1995
Sanofi Aventis Us	AMARYL	glimepiride	TABLET;ORAL	020496-003	Nov 30, 1995

International Patents for AMARYL

See the table below for patents covering AMARYL around the world.

Country	Patent Number	Title	Estimated Expiration
Spain	498228
Norway	803855
Spain	498224

Supplementary Protection Certificates for AMARYL

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
1174135	SPC/GB10/011	United Kingdom		PRODUCT NAME: THE COMBINATION OF PIOGLITAZONE OPTIONALLY IN THE FORM OF A PHARMACEUTICALLY ACCEPTABLE SALT, ESPECIALLY THE HYDROCHLORIDE SALT, AND GLIMEPIRIDE.; REGISTERED: UK EU/1/06/366/001 20070108; UK EU/1/06/366/002 20070108; UK EU/1/06/366/003 20070108; UK EU/1/06/366/004 20070108; UK EU/1/06/366/005 20070108; UK EU/1/06/366/006 20070108; UK EU/1/06/366/019 20070108; UK EU/1/06/366/020 20070108; UK EU/1/06/366/021 20070108; UK EU/1/06/366/022 20070108; UK EU/1/06/366/013 20070108; UK EU/1/06/366/014 20070108; UK EU/1/06/366/015 20070108; UK EU/1/06/366/016 20070108; UK EU/1/06/366/017 20070108; UK EU/1/06/366/018 20070108; UK EU/1/06/366/007 20070108; UK EU/1/06/366/008 20070108; UK EU
0031058	SPC/GB97/012	United Kingdom
0031058	98C0008	Belgium		PRODUCT NAME: TAZAROTENE; NAT. REGISTRATION NO/DATE: NL22604 19970922; FIRST REGISTRATION: DE - 37393.00.00 19961203

AMARYL: Market Dynamics and Financial Trajectory

Last updated: February 19, 2026

What is AMARYL and Its Therapeutic Area?

AMARYL (glimepiride) is an oral antidiabetic medication belonging to the sulfonylurea class. It is prescribed for the management of type 2 diabetes mellitus. The drug functions by stimulating the pancreas to produce more insulin and increasing the sensitivity of peripheral tissues to insulin, thereby lowering blood glucose levels. Glimepiride was first approved by the U.S. Food and Drug Administration (FDA) in 1995. Its primary mechanism of action involves binding to the sulfonylurea receptor on pancreatic beta cells, closing ATP-sensitive potassium channels, which leads to membrane depolarization and subsequent insulin release.

Patent Landscape and Exclusivity Period

The original patent for glimepiride was granted to Hoechst AG (later Aventis, then Sanofi-Aventis, and now Sanofi). U.S. Patent No. 4,377,580, titled "2-amino-4,6-dialkoxy-pyrimidinyl-sulfonylureas," covering glimepiride, was filed on December 31, 1980, and issued on March 27, 1984. This patent provided market exclusivity. However, subsequent patents may have covered specific formulations, manufacturing processes, or new uses, potentially extending exclusivity for certain aspects of the drug.

The primary patent protection for glimepiride has long expired. Generic versions of glimepiride became available in the United States following the expiration of key patents. The last period of significant patent protection likely concluded in the early 2010s for the original compound. For instance, Orange Book listings indicate that the latest expiring patents for Amaryl (glimepiride) were related to formulations and had expiration dates around 2013-2014. This opened the door for significant generic competition.

Market Entry and Competition

Following the expiration of primary patents, AMARYL faced intense competition from generic manufacturers. The market for type 2 diabetes medications is highly competitive, with numerous drug classes and individual agents vying for market share. The entry of generic glimepiride significantly reduced the price of the active pharmaceutical ingredient and the finished dosage forms.

Key competitors in the broader type 2 diabetes market include:

• Metformin: The first-line therapy for most patients with type 2 diabetes, often used in combination with other agents.
• DPP-4 Inhibitors: Examples include sitagliptin (Januvia), saxagliptin (Onglyza), and linagliptin (Tradjenta).
• SGLT2 Inhibitors: Examples include empagliflozin (Jardiance), canagliflozin (Invokana), and dapagliflozin (Farxiga).
• GLP-1 Receptor Agonists: Examples include liraglutide (Victoza), semaglutide (Ozempic, Rybelsus), and dulaglutide (Trulicity).
• Other Sulfonylureas: Glyburide and glipizide are older sulfonylureas that also face generic competition.

The availability of multiple therapeutic options and the widespread availability of generic glimepiride have placed downward pressure on pricing and market share for branded AMARYL.

Sales Performance and Financial Trajectory

Sanofi, the originator of AMARYL, experienced a significant decline in sales of the branded product following the advent of generic competition. Sales figures illustrate this trend:

• Peak Sales: While precise peak sales figures for branded AMARYL as a standalone product are difficult to isolate due to reporting consolidation, sulfonylureas as a class, including glimepiride, were once blockbuster drugs. Sales for Sanofi’s diabetes franchise, which included AMARYL and other agents, reached billions of dollars annually in the mid-2000s.
• Post-Generic Entry: Following patent expirations and generic introductions, sales of branded AMARYL have substantially decreased. By the late 2010s and early 2020s, branded AMARYL sales represented a small fraction of their historical peaks, as generic glimepiride dominates prescription volume. For example, in 2022, Sanofi reported global sales of its diabetes franchise, but the contribution from older, off-patent molecules like glimepiride is minimal and often not individually disclosed in detail, signifying their mature lifecycle stage.
• Generic Market Value: The global market for generic glimepiride remains substantial, driven by its efficacy, affordability, and established track record. The value resides with generic manufacturers rather than the innovator. The overall market for oral antidiabetics, including generics, is in the tens of billions of dollars annually.

The financial trajectory of branded AMARYL is a classic example of a product entering the mature stage of its lifecycle, transitioning from a high-revenue innovator drug to a low-cost generic.

Regulatory and Market Access Landscape

AMARYL, like all pharmaceuticals, operates within a complex regulatory environment. The FDA oversees its approval for safety and efficacy in the U.S. The drug is listed in the FDA's Approved Drug Products with Therapeutic Equivalence Evaluations (Orange Book), which details patent and exclusivity information.

Market access for AMARYL, particularly the branded version, is influenced by:

• Formulary Placement: Insurance companies and pharmacy benefit managers (PBMs) determine which drugs are covered on their formularies and at what tier. Branded AMARYL would typically be placed on a higher tier, reflecting higher co-pays, compared to generic glimepiride.
• Reimbursement Policies: Payer policies often favor generic alternatives due to their cost-effectiveness. This incentivizes physicians to prescribe generic glimepiride.
• Clinical Guidelines: Professional medical societies and diabetes management guidelines often recommend metformin as a first-line agent. While sulfonylureas like glimepiride are still recommended, they are often considered second-line or third-line therapies, especially in light of newer drug classes with improved cardiovascular and renal outcomes profiles.
• Physician Prescribing Habits: Physician preferences, familiarity with the drug, patient response, and cost considerations all impact prescribing patterns. The widespread availability and affordability of generic glimepiride have led to a significant shift in physician prescribing away from the branded product.

Future Market Outlook

The future market outlook for branded AMARYL is limited. Its primary role is now fulfilled by generic glimepiride.

• Continued Generic Dominance: Generic glimepiride will continue to be a widely prescribed and affordable option for type 2 diabetes management globally. Its cost-effectiveness ensures its place in treatment regimens, particularly in resource-constrained settings.
• Limited Innovation for Branded AMARYL: Without new patentable innovations (e.g., novel formulations with improved delivery or reduced side effects, or combination therapies), the branded product is unlikely to regain significant market share or revenue.
• Market Share Erosion: Branded AMARYL will continue to see its market share erode as generic penetration remains high and newer diabetes medications with distinct clinical benefits gain traction.
• Therapeutic Niche: While newer classes of antidiabetics offer benefits such as cardiovascular protection and weight loss, sulfonylureas like glimepiride remain important for their efficacy in lowering HbA1c and their low cost. Glimepiride will likely maintain a therapeutic niche, primarily in its generic form, as an add-on therapy or for patients who cannot tolerate or afford newer agents.

The overall market for antidiabetic drugs is growing due to the rising global prevalence of diabetes. However, this growth is largely driven by newer, more complex therapies and the increasing number of patients, rather than increased utilization of older, off-patent drugs like branded AMARYL.

Key Takeaways

• AMARYL (glimepiride) is an established sulfonylurea for type 2 diabetes.
• Primary patents for glimepiride have expired, leading to extensive generic competition.
• Branded AMARYL sales have significantly declined from their peak due to generic availability and the emergence of newer antidiabetic drug classes.
• The market value for glimepiride now resides primarily with generic manufacturers.
• Future market prospects for branded AMARYL are minimal, with generic glimepiride expected to remain a cost-effective treatment option.

Frequently Asked Questions

1. What is the current patent status of AMARYL (glimepiride)? The primary patents covering the active pharmaceutical ingredient glimepiride have expired. While there might be secondary patents on specific formulations or manufacturing processes, these have also largely expired or are nearing expiration, allowing for broad generic availability.

2. How has the introduction of generic glimepiride impacted the market for branded AMARYL? The introduction of generic glimepiride led to a substantial decrease in the price of the drug and a significant erosion of market share for branded AMARYL. Prescribers and patients have largely transitioned to the more affordable generic versions.

3. What are the main therapeutic alternatives to glimepiride in the management of type 2 diabetes? Key therapeutic alternatives include metformin, DPP-4 inhibitors (e.g., sitagliptin), SGLT2 inhibitors (e.g., empagliflozin), and GLP-1 receptor agonists (e.g., liraglutide). These newer drug classes often offer additional benefits beyond glycemic control, such as cardiovascular and renal protection.

4. What is the projected market size for generic glimepiride in the next five years? While precise projections for generic glimepiride alone are difficult to isolate, the overall oral antidiabetic market is expected to grow. Generic glimepiride will likely maintain a steady demand due to its low cost and efficacy, particularly in emerging markets and as an add-on therapy, but its revenue contribution will remain limited by pricing.

5. Does Sanofi still market branded AMARYL, and what is its current revenue contribution? Sanofi continues to market branded AMARYL, but its revenue contribution to the company's overall sales is minimal and not typically disclosed as a separate line item. The majority of glimepiride prescriptions are filled with generic products.

Citations

[1] U.S. Food and Drug Administration. (n.d.). Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations. Retrieved from https://www.fda.gov/drugs/information-drug-dosage-forms-and-compounding/orange-book-approved-drug-products-therapeutic-equivalence-evaluations [2] U.S. Patent No. 4,377,580. (1984). 2-amino-4,6-dialkoxy-pyrimidinyl-sulfonylureas. [3] Sanofi. (2023). Annual Reports and Financial Statements. (Various Years). [4] Pharmaceutical market research reports. (Various data sources not individually cited, representing aggregated industry analysis).